Abstract
【Introduction】Percutaneous transluminal angioplasty (PTA) is necessary to maintain vascular access but is also a painful procedure for hemodialysis patients. Therefore, we decided to use midazolam for pain relief during the procedure, and assessed its safety and effectiveness.【Objective & Method】We used midazolam during PTA for 44 cases (22 outpatients) from August 2013 to May 2014 at Tosei General Hospital. Patients and physicians evaluated the pain assessed by Visual Analog Scale (VAS). We investigated complications, appropriate dosage for dialysis patients, and medication interaction.【Results】Midazolam provided significant pain relief (82±18 mm vs. 11±32 mm ; p<0.001). All patients except one wanted further midazolam administration. Physicians assessed the pain as being more severe than the patients did (38±38 mm vs. 15±25 mm ; p<0.01) The average dosage of midazolam was 0.06±0.02 mg/kg, and patients using sleep medication required a significantly larger dosage (p<0.05). Complications were glossoptosis or reduction in SpO2 (9 cases) and restlessness (2 cases), but no serious complications occurred.【Conclusion】Midazolam is safe for dialysis patients, and it is effective for pain relief during PTA.
